home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  April 28, 2024
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 467 active entries

JN-International Medical Corporation

2720 North 84th Street
Omaha
United States of America, Nebraska

Phone: 402-884-3477
Fax: 402-614-4437

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

JN-International Medical Corporation (JNIMC), a U.S. based private biopharmaceutical corporation, has been developing vaccines for infectious disease and neurological disorders. Emphasis on our 20-years of basic research combined with an applied focus on specific medical needs was instrumental to success and growth of this corporation.  If it wasn’t apparent before, JNIMC’s ground breaking discovery of a therapeutic and preventive vaccine for major infectious diseases and neurological disorders, makes abundantly clear that we are living in an era of “contested” diseases. All sorts of contorted linguistic anomalies have arisen from the field of contested disorders such as Hepatitis C, Herpes, Stroke, Parkinson, Alzheimer, Huntington and Epilepsy even in this the 21st century. The strategic vision of JNIMC is to use novel technologies for generations of innovative vaccines for the prevention of these  infectious diseases and “cure-unknown” major neurological disorders.  

Marketing strategy for JN-International Since 1998, JN manufactures vaccines and diagnostics in contract manufacture facilities and delivers to international markets. The international subsidiaries of JN unit’s growing penetration of the vaccines and diagnostics market positions the company to benefit from generating revenues from international market segment especially from Africa and Asia. The synergies inherent in JN’s business model are based on the Company’s core technology through the research for newer diagnostics for disease screening in developing countries. In the past, this approach has been demonstrated twice as it relates to HIV and TB diagnostics in South East Asia, Africa and South America. The second synergy showed high success rate in the supply of childhood and disease outbreak vaccines for sub-Saharan Africa and South Asia. JN-International - Côte d'Ivoire Corporation in Africa distributes several vaccine products these products include Typhoid, Measles, and Yellow fever, Rabies, Hepatitis B, DTP, Polio and Meningococcal.

VACCINS POUR L'AFRIQUE SUBSAHARIENNE / Vaccines for sub-Saharan Africa: 

JN-International - Côte d'Ivoire en Afrique Société distribue des produits de plusieurs vaccins achetés auprès de fabricants réputés en Inde, en Europe et aux USA. Ces produits comprennent la fièvre typhoïde, la rougeole et la fièvre jaune, rage, hépatite B, DTC, la polio et la méningite A,C,Y & W135.  Organisation mondiale de la santé vaccins approuvés Vaccins de l'OMS répondre pharmacopées spécifications et des États-Unis et l'UE.  CONTACT subsaharienne bureaux en Afrique pour l'approvisionnement en vaccins avec crédit jusqu'à concurrence de 6 -12 mois sur LC.  

CONTACT Sub-Saharan Africa Offices for Vaccine Supply  with Credit  up to 6  -12 months on LC   

 

 

 

 



Selected Categories:
Product Company   Service Company
Biopharma
- Research
Biotech
- Research
Diagnostics
- Immunoassay
- Medical
Supplier
- Distributor
- Medical
- Research

Last update of this entry: April 16, 2010

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.